Search Results for "azithromycin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for azithromycin. Results 1 to 10 of 63 total matches.
Clarithromycin and Azithromycin
The Medical Letter on Drugs and Therapeutics • May 15, 1992 (Issue 870)
Clarithromycin and Azithromycin ...
Clarithromycin (Biaxin - Abbott) and azithromycin (Zithromax - Pfizer), two macrolide antibiotics chemically related to erythromycin, have been approved by the US Food and Drug Administration for treatment of respiratory, skin, and skin structure infections. Azithromycin has also been approved for treatment of nongonococcal urethritis and cervicitis caused by Chlamydia trachomatis.
In Brief: Safety of Azithromycin
The Medical Letter on Drugs and Therapeutics • Jun 11, 2012 (Issue 1392)
In Brief: Safety of Azithromycin ...
Recently published results of a large, carefully conducted retrospective study indicated that use of the antibiotic azithromycin (Zithromax, and others) may increase the risk of cardiovascular death, especially in patients with a high baseline risk of cardiovascular disease.1 One possible mechanism is prolongation of the QT interval, which is known to occur rarely with azithromycin and more frequently with the other macrolide antibiotics erythromycin (Erythrocin, and others) and clarithromycin (Biaxin, and others).Among the patients who received 347,795 prescriptions for azithromycin, there...
In Brief: FDA Azithromycin Warning
The Medical Letter on Drugs and Therapeutics • Apr 01, 2013 (Issue 1413)
In Brief: FDA Azithromycin Warning ...
The FDA has announced that it is requiring changes in the labeling of the macrolide antibiotic azithromycin (Zithromax, Zmax) to warn about the risk of QT prolongation and cardiac arrhythmias.1 The new warnings are based on a retrospective study in The New England Journal of Medicine (reviewed previously in The Medical Letter2), which found that among patients who received 347,795 prescriptions for azithromycin, there were 29 cardiovascular deaths, a significantly higher rate than the 42 that occurred among patients who received 1,348,672 prescriptions for amoxicillin (which does not prolong...
Ophthalmic Azithromycin (AzaSite)
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
Ophthalmic Azithromycin (AzaSite) ...
The FDA has approved azithromycin 1% ophthalmic solution (AzaSite - Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a controlled-release delivery system that keeps the drug in the eye for several hours.
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 28, 2005 (Issue 1218)
Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia ...
Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.
In Brief: New Recommendations for Gonococcal Infection
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
azithromycin for treatment
of uncomplicated gonorrhea.2 Coadministration of
azithromycin was recommended ...
The CDC has issued new recommendations for
treatment of gonococcal infection. A single 500-mg
IM dose (1000 mg in patients weighing ≥150 kg) of the
third-generation cephalosporin ceftriaxone is now the
treatment of choice for patients with uncomplicated
urogenital, rectal, or pharyngeal gonorrhea.
Drugs for Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
hours), azithromycin has some advantages. It is the drug of choice for travelers to areas
with a high ...
The most common cause of travelers' diarrhea, usually a self-limited illness without fever lasting several days, is infection with noninvasive enterotoxigenic (ETEC) or enteroaggregative (EAEC) strains of Escherichia coli. Campylobacter, Shigella, Salmonella, Aeromonas, viruses and parasites are less common.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
is an effective alternative. A single dose
of oral azithromycin is less effective than doxycycline
for rectal C ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Clarithromycin in Patients with Coronary Artery Disease
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
may be resistant to macrolides and clindamycin.
7. Azithromycin 500 mg PO x 1, then 250 mg once/d x 4 days ...
The FDA has warned that use of the macrolide
antibiotic clarithromycin (Biaxin, and generics) may
increase the risk of cardiovascular morbidity and
mortality in patients with heart disease.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
,
and atypical pathogens1
Delafloxacin has activity against MRSA
Macrolides
(azithromycin, clarithromycin)
H ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.